Offerings (SEC Form D)
Each filing as reported by the issuer, newest first. Open a row for the full plain-English detail. D = original notice, D/A = amendment.
Offerings at a glance — 1 offering, 5 filings (one row per SEC file number)
| File no. | Original Form D | Latest filing | Amendments | Offered (latest) | Sold (latest) | Industry (latest) |
|---|
| 021-73213 | Jul 20, 2009 EDGAR ↗ | Nov 20, 2009 D/A EDGAR ↗ | 1 latest Nov 20, 2009 | $6,653,000 | $6,653,000 | Biotechnology |
Offerings are grouped by SEC file number; rows without a file number (not yet retrieved from EDGAR) are shown as their own offering until the link is fetched.
Nov 20, 2009 D/A Biotechnology — $6,653,000 sold of $6,653,000 · 10 investors EDGAR ↗
| Filing | Form D/A (amendment) filed Nov 20, 2009 · amends 0001314932-09-000007 ↗SEC file no. 021-73213 · accession 0001314932-09-000008 · filing 5 of 5 in this offering |
|---|
| Raise progress | $6,653,000 sold of $6,653,000 offered (100%) · $0 remaining · first sale Sep 30, 2009 |
|---|
| Filing timing | Date of first sale: Sep 30, 2009 · Original Form D filed: Jul 20, 2009 (72 days before first sale) · This amendment (Form D/A) filed: Nov 20, 2009 This row is an amendment. Rule: the original Form D is generally due within 15 days after the first sale; the rule sets no deadline measured from an amendment. Dates shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,233 days (17.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. This filing is an amendment dated Nov 20, 2009. Most recent amendment for this offering in our index: this filing, Nov 20, 2009. Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 10 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2004 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Todd Potokar, CEO and President (Nov 17, 2009) |
|---|
| Changes vs previous filing | - total sold: $250,000 (Oct 8, 2009) → $6,653,000 (Nov 20, 2009)
- total offering: $4,650,000 (Oct 8, 2009) → $6,653,000 (Nov 20, 2009)
- remaining: $4,400,000 (Oct 8, 2009) → $0 (Nov 20, 2009)
- related persons added (Nov 20, 2009): Limor Sundach, David Cohen
- related persons no longer listed (Nov 20, 2009): Dalia Megiddo
Compared with the D filed Oct 8, 2009 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Oct 8, 2009 D Biotechnology — $250,000 sold of $4,650,000 · 10 investors EDGAR ↗
| Filing | Form D filed Oct 8, 2009SEC file no. 021-73213 · accession 0001314932-09-000007 · filing 4 of 5 in this offering |
|---|
| Raise progress | $250,000 sold of $4,650,000 offered (5%) · $4,400,000 remaining · first sale Sep 30, 2009 |
|---|
| Filing timing | Date of first sale: Sep 30, 2009 · Form D filed: Oct 8, 2009 (8 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,233 days (17.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 20, 2009 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 10 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2004 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Todd Potokar, CEO and President (Oct 5, 2009) |
|---|
| Changes vs previous filing | - total sold: $750,000 (Sep 23, 2009) → $250,000 (Oct 8, 2009)
- total offering: $750,000 (Sep 23, 2009) → $4,650,000 (Oct 8, 2009)
- remaining: $0 (Sep 23, 2009) → $4,400,000 (Oct 8, 2009)
- date of first sale: Sep 14, 2009 (Sep 23, 2009) → Sep 30, 2009 (Oct 8, 2009)
Compared with the D filed Sep 23, 2009 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Sep 23, 2009 D Biotechnology — $750,000 sold of $750,000 · 10 investors EDGAR ↗
| Filing | Form D filed Sep 23, 2009SEC file no. 021-73213 · accession 0001314932-09-000006 · filing 3 of 5 in this offering |
|---|
| Raise progress | $750,000 sold of $750,000 offered (100%) · $0 remaining · first sale Sep 14, 2009 |
|---|
| Filing timing | Date of first sale: Sep 14, 2009 · Form D filed: Sep 23, 2009 (9 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,249 days (17.1 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 20, 2009 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 10 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2004 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Todd Potokar, CEO and President (Sep 23, 2009) |
|---|
| Changes vs previous filing | - total sold: $600,000 (Aug 13, 2009) → $750,000 (Sep 23, 2009)
- total offering: $600,000 (Aug 13, 2009) → $750,000 (Sep 23, 2009)
- investors: 9 (Aug 13, 2009) → 10 (Sep 23, 2009)
- date of first sale: Jul 31, 2009 (Aug 13, 2009) → Sep 14, 2009 (Sep 23, 2009)
Compared with the D filed Aug 13, 2009 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Aug 13, 2009 D Biotechnology — $600,000 sold of $600,000 · 9 investors EDGAR ↗
| Filing | Form D filed Aug 13, 2009SEC file no. 021-73213 · accession 0001314932-09-000005 · filing 2 of 5 in this offering |
|---|
| Raise progress | $600,000 sold of $600,000 offered (100%) · $0 remaining · first sale Jul 31, 2009 |
|---|
| Filing timing | Date of first sale: Jul 31, 2009 · Form D filed: Aug 13, 2009 (13 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,294 days (17.2 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 20, 2009 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 9 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity |
|---|
| Entity details | Organized in DELAWARE · formed 2004 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Todd Potokar, CEO and President (Aug 13, 2009) |
|---|
| Changes vs previous filing | - total sold: $7,300,000 (Jul 20, 2009) → $600,000 (Aug 13, 2009)
- total offering: $7,300,000 (Jul 20, 2009) → $600,000 (Aug 13, 2009)
- investors: 36 (Jul 20, 2009) → 9 (Aug 13, 2009)
- date of first sale: Jul 6, 2009 (Jul 20, 2009) → Jul 31, 2009 (Aug 13, 2009)
- securities offered: Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise (Jul 20, 2009) → Equity (Aug 13, 2009)
- related persons no longer listed (Aug 13, 2009): Brian Cameron
Compared with the D filed Jul 20, 2009 ( EDGAR ↗). Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Amendment history as filed; no conclusion is drawn. |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Jul 20, 2009 D Biotechnology — $7,300,000 sold of $7,300,000 · 36 investors EDGAR ↗
| Filing | Form D filed Jul 20, 2009SEC file no. 021-73213 · accession 0001314932-09-000004 · filing 1 of 5 in this offering |
|---|
| Raise progress | $7,300,000 sold of $7,300,000 offered (100%) · $0 remaining · first sale Jul 6, 2009 |
|---|
| Filing timing | Date of first sale: Jul 6, 2009 · Form D filed: Jul 20, 2009 (14 days after first sale) Rule: a Form D is generally due within 15 days after the first sale. Both dates are shown as reported; no conclusion is drawn. |
|---|
| Time since first sale | 6,319 days (17.3 years) |
|---|
| Annual amendments | Issuer reported the offering is not expected to last more than one year. Most recent amendment for this offering in our index: Nov 20, 2009 (EDGAR ↗). Rule: an ongoing offering generally files an amendment at least annually. Dates shown as reported; no conclusion is drawn. |
|---|
| Investors | 36 total · issuer reported no non-accredited investors |
|---|
| Exemption claimed | Rule 506 (filed before Sept 2013, when 506 was split into 506(b) and 506(c)) |
|---|
| Minimum investment accepted | $1 |
|---|
| Securities offered | Equity; Option, warrant or other right to acquire; Security to be acquired upon exercise |
|---|
| Entity details | Organized in DELAWARE · formed 2004 · revenue range: Decline to Disclose (state and year as reported on the issuer's latest filing) As reported by the issuer on Form D (Items 1–2 and 5). |
|---|
| Industry | Biotechnology |
|---|
| Who is paid to sell it | No sales compensation recipients listed on this filing. |
|---|
| Money to insiders | Sales commissions: $0 · Finder's fees: $0 · Proceeds to officers, directors, promoters: $0 |
|---|
| Signed by | Todd Potokar, CEO and President (Jul 20, 2009) |
|---|
| Market context | Not computed — the exemption as filed is Rule 506 before the Sept 2013 split into 506(b) and 506(c) (see Exemption claimed); ranges are computed only for offerings claiming Rule 506(b) or 506(c), compared with the last 5 years of filings. |
|---|
| Source | This filing on SEC EDGAR ↗ · retrieved from the SEC Form D bulk data set · PartnerFacts data last updated Oct 23, 2026, 5:45 PM ET |
|---|
Amendment history — 1 amendment on this page, each compared with the filing before it in the same offering
| Amendment filed | File no. | Compared with | What changed (both values as filed) |
|---|
| Nov 20, 2009 EDGAR ↗ | 021-73213 | Oct 8, 2009 D | total sold: $250,000 (Oct 8, 2009) → $6,653,000 (Nov 20, 2009) · total offering: $4,650,000 (Oct 8, 2009) → $6,653,000 (Nov 20, 2009) · remaining: $4,400,000 (Oct 8, 2009) → $0 (Nov 20, 2009) · and 2 more (open the filing above) |
Fields compared: total sold, total offering, remaining, investors, non-accredited investors (count), non-accredited investors reported, minimum investment, sales commissions, finder's fees, proceeds to insiders, date of first sale, industry, fund type, exemption, revenue range, net asset value range, securities offered, may last more than one year, related persons, sales-compensation recipients. Values as filed; no conclusion is drawn.
All Form D filings for this CIK on SEC EDGAR ↗. History: 0 new offerings in the last 12 months (new offering = a Form D that is not an amendment) · most recent filing Nov 20, 2009. Industry as reported, by offering: One offering, reported as Biotechnology (Jul 20, 2009).
Key people 8
Officers, directors and promoters the issuer itself named on its Form D. Tap a name for every other deal they are on.
| Name | Relationship | Address state | On filings (first → last) | Also listed on |
|---|
| CC Charles Cohen | Director | NJ | Jul 20, 2009 → Nov 20, 2009 on 5 of 5 filings listed on the latest filing | — |
| DC David Cohen | Director | NJ | Nov 20, 2009 on 1 of 5 filings listed on the latest filing | 1 other issuer |
| I Impliant entity | Promoter | Israel (as filed: L3) | Jul 20, 2009 → Nov 20, 2009 on 5 of 5 filings listed on the latest filing | — |
| LS Limor Sundach | Director | NJ | Nov 20, 2009 on 1 of 5 filings listed on the latest filing | — |
| TP Todd Potokar | Executive Officer, Director | NJ | Jul 20, 2009 → Nov 20, 2009 on 5 of 5 filings listed on the latest filing | — |
| ZS Zvika Slovin | Director | NJ | Jul 20, 2009 → Nov 20, 2009 on 5 of 5 filings listed on the latest filing | — |
| DM Dalia Megiddo | Director | NJ | Jul 20, 2009 → Oct 8, 2009 on 4 of 5 filings not listed on the latest filing (Nov 20, 2009) | — |
| BC Brian Cameron | Director | NJ | Jul 20, 2009 on 1 of 5 filings not listed on the latest filing (Nov 20, 2009) | — |
Executive officers, directors and promoters as self-reported by the issuer, one row per person. Spellings of the same name (same first and last name, or the same full name that EDGAR split differently into middle and last name) with no conflicting middle initial are shown on one row (none on this issuer); dates and counts come from the filings that list each name. Licensed persons: FINRA BrokerCheck ↗ · SEC IAPD ↗.
Connections
Other issuers listing the same people:
Shared address: this business address appears on filings for 10 other issuers. Stated as a count only (suite numbers ignored) — many addresses are shared office buildings or registered agents. As of Oct 23, 2026, 5:45 PM ET.
Address of record is shared by 11 issuers in SEC Form D filings (shared office, PartnerFacts count as of Oct 23, 2026, 5:45 PM ET) — not used to group this issuer.
Other offering types (Regulation A and Regulation Crowdfunding)
Searched SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 (51,358 records as of Oct 23, 2026, 8:41 PM ET) — nothing matched this name.
Adviser registration (Form ADV)
Searched SEC Form ADV bulk data (registered + exempt reporting advisers) (24,962 records as of Oct 2, 2026, 8:00 AM ET) — nothing matched Impliant Inc.
Meta advertising
No Meta Pixel ids or Facebook / Instagram page links on file for Impliant Inc as of Oct 24, 2026 — the sponsor website is read for them once it is on file (runs automatically). Meta Ad Library: not searched by PartnerFacts (no API access); a one-tap Ad Library search is under Look further.
Public profiles
Public profiles official links and public statements, each with its source and date
No website or social profile named in Impliant Inc's SEC filings (Form C, Reg A, Form ADV; checked Oct 24, 2026). Web search for this name: #367,777 of 374,652 in line (14 issuers searched so far).
Sources searched for a website: Form C data set (issuer websites as filed), Form ADV data set (Item 1.I of matched advisers) — as of Oct 23, 2026, 11:20 PM ET: none on file for this issuer. The sponsor website, the Internet Archive and GDELT news index are read only once a site is on file; a sponsor's website comes from the issuer's own filings (Form C issuer website; EDGAR company profile), an approved profile claim, Form ADV Item 1.I of its matched adviser, or a web search for the issuer name confirmed on the site's own homepage. We never collect personal or family accounts.
Entity standing: not checked (no official programmatic source for NJ yet).
Export this report as PDF (all source links + data timestamp) · Premium
Request diligence pack (Premium) PartnerFacts asks the sponsor for the standard information pack and delivers it to you labelled "provided by the sponsor".
Corrections log
No corrections have been requested for this page.
Filing-to-filing changes are in Amendment history above.